Alpha Cognition Inc (ACOG.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:ACOG - CA02074J2048 - Common Stock
ACOG.CA Key Statistics, Chart & Performance
The current stock price of ACOG.CA is 0.39 CAD. In the past month the price increased by 11.43%. In the past year, price decreased by -37.1%.
ACOG.CA Latest News, Press Relases and Analysis
ACOG.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 449.77M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 385.84M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 177.20M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 115.94M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.25 | 53.19M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.88M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 32.98M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 21.30M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 13.57M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.75M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 7.61M |
Related stock screener links
About ACOG.CA
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
Company Info
Alpha Cognition Inc
301 - 1228 Hamilton Street, Null
Vancouver BRITISH COLUMBIA V6B 2E6 CA
CEO: Michael McFadden
Employees: 0
Phone: 16045649244.0
Alpha Cognition Inc / ACOG.CA FAQ
Can you describe the business of Alpha Cognition Inc?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
What is the current price of ACOG stock?
The current stock price of ACOG.CA is 0.39 CAD. The price decreased by -14.29% in the last trading session.
What is the dividend status of Alpha Cognition Inc?
ACOG.CA does not pay a dividend.
How is the ChartMill rating for Alpha Cognition Inc?
ACOG.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does Alpha Cognition Inc belong to?
Alpha Cognition Inc (ACOG.CA) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of Alpha Cognition Inc (ACOG.CA) based on its PE ratio?
Alpha Cognition Inc (ACOG.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
What is Alpha Cognition Inc worth?
Alpha Cognition Inc (ACOG.CA) has a market capitalization of 33.89M CAD. This makes ACOG.CA a Nano Cap stock.
ACOG.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ACOG.CA. When comparing the yearly performance of all stocks, ACOG.CA turns out to be only a medium performer in the overall market: it outperformed 64.51% of all stocks.
ACOG.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACOG.CA. ACOG.CA may be in some trouble as it scores bad on both profitability and health.
ACOG.CA Financial Highlights
Over the last trailing twelve months ACOG.CA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 12.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -239.04% | ||
| ROE | -839.02% | ||
| Debt/Equity | 0.89 |
ACOG.CA Forecast & Estimates
6 analysts have analysed ACOG.CA and the average price target is 3.06 CAD. This implies a price increase of 684.62% is expected in the next year compared to the current price of 0.39.